Two very different places to do the same job
The five functions exist in both, but the experience of working in them is not the same. Understanding the difference before you apply makes it far likelier that the role you take suits your temperament as well as your skills.
Established, global, process-led
Companies with marketed products, tens of thousands of staff, and decades of infrastructure.
Emerging, focused, fast-moving
Often pre-commercial or newly commercial, built around a small number of assets.
- Narrow, deep, and highly specialised. Functions are separated into distinct teams, so a Safety Scientist does safety science, a labeling specialist does labeling, and a publications lead does publications. You go deep on one craft.
- More role variety overall simply because headcount is larger — niche positions like Signal Detection Scientist, Regulatory CMC Specialist, or Plain Language Summary Specialist genuinely exist as standalone jobs.
- Defined job families and formal levelling, so the difference between a Manager, an Associate Director, and a Director is written down and reasonably consistent.
- Broad, blended, and fluid. One person often covers ground that three people would cover in large pharma — a Medical Director at a clinical-stage biotech may handle medical monitoring, safety input, regulatory responses, and KOL engagement in the same week.
- Fewer specialised roles, but far more ownership per person. You will touch the whole product story rather than one slice of it.
- Titles are looser and often run a level higher than the pharma equivalent for comparable scope — worth remembering when comparing offers.
- Process-driven and matrixed. Established SOPs exist for almost everything, decisions move through defined governance, and alignment across functions is expected before action.
- Structured onboarding and formal training. For a clinician new to industry this is genuinely valuable — you are taught the system rather than left to reverse-engineer it.
- The trade-off is pace. Consensus takes time, and the distance between your work and a visible company outcome can feel long.
- Flat, fast, and comfortable with ambiguity. Fewer layers between you and the executive team; it is normal to present directly to the CMO or CEO within your first months.
- Much less process. Sometimes the SOP does not exist yet and writing it is your job. People who like building systems thrive; people who want a clear playbook can struggle.
- Intensity is tied to milestones. The months before a data readout or a regulatory submission are demanding in a way that is hard to appreciate from outside.
- Higher, steadier base salary with a reliable annual cash bonus tied to a mix of individual and company performance.
- Equity is usually restricted stock in a large, publicly traded, liquid company — it has real and reasonably predictable value, but it will not transform your net worth.
- Stronger benefits, retirement matching, and far more income stability. The total package is easier to forecast, which matters if you are leaving a clinical salary and supporting a family.
- Comparable or slightly lower base, a smaller cash bonus, and a meaningfully larger equity grant — typically stock options at a small or clinical-stage company.
- That equity is the real variable. It can be worth a great deal if the company succeeds, and nothing at all if a pivotal trial fails. Understand your strike price, vesting schedule, and the company's cash runway before you sign.
- Higher ceiling, higher variance. Treat the equity as genuine upside, not as guaranteed compensation you can budget around.
- Predictable and well-signposted. Promotion cycles, levelling criteria, and the path from Director to Executive Director to VP are documented and broadly followed.
- Slower to senior titles, but the progression is durable and portable — a Director title from a major pharma company is understood everywhere.
- Real internal mobility: moving between therapeutic areas, functions, or countries without changing employer is a normal and supported career move.
- Faster, broader, and less certain. Scope can expand dramatically in a short time, and people reach senior titles years earlier than their large-pharma peers.
- You accumulate unusually broad experience quickly, which is excellent preparation for senior leadership — a large share of Chief Medical Officers come up through biotech for exactly this reason.
- The risk is real. A failed readout or a funding gap can mean layoffs regardless of your performance. Many biotech careers involve moving companies more often than pharma careers do.
It is a spectrum, not a binary
The cleanest way to think about this is company size and stage rather than the label on the door. A large, long-commercial biotech operates far more like traditional pharma than like a twenty-person startup, and a small specialty pharma company can feel entirely biotech. When you evaluate an employer, ask how many people are in the function you would join and whether the company has products on the market — those two answers predict your day-to-day experience better than the word "pharma" or "biotech" ever will.
Which should you target first?
If you are making your first move out of clinical practice, large pharma and established biotech generally offer more structured onboarding, formal training, and a documented path — genuinely useful when you are still learning how the industry works. If you already have industry exposure, or you want breadth quickly and can tolerate risk, a smaller biotech will hand you far more scope far sooner. Neither is the “correct” first step. Match it honestly to how much ambiguity you want to absorb while you are also learning an entirely new professional environment.